Bubble Super Clear: serum naming, study groups and the posted label

The manufacturer calls Super Clear an acne serum. The label’s fuller name is Bubble Super Clear Blemish Prevention Serum, and its product table describes a salicylic-acid emulsion. Its posted update date is May 3, 2024. These descriptions belong to the identified product record; they do not show that two different physical products were examined. Manufacturer serum page and emulsion label.

A label date is also different from a bottle’s manufacture or purchase date. The version-record guide explains why that distinction matters. This review retains both names and the source date rather than replacing the label’s language with an assumed current package specification.

The label names salicylic acid 2% and gives acne medication as the purpose. Its inactive list includes water, glycerin, squalane, colloidal oatmeal and other components. The manufacturer page highlights selected ingredients, including willow bark extract, but that shorter story should not replace the posted list. The captured complete inactive list does not name niacinamide. Active and inactive panels.

FDA describes how purpose, uses, warnings and inactive ingredients serve separate functions in Drug Facts. Those fields help readers distinguish a formula declaration from a claim about what it does. They do not provide independently measured ingredient quantities, a way to reproduce the serum or an assurance about an actual bottle’s contents. FDA panel explanation.

Bubble attributes improvement in the appearance, size and redness of breakouts to an independent clinical study with 31 subjects. The advertised result concerns a one-week endpoint. This is the manufacturer’s summary of a stated clinical group, rather than a report this publication independently evaluated in full. Clinical-result wording.

The account does not supply the complete report or comparator in the material acquired. It cannot establish a probability of improvement for another person, and the advertised period should not become a deadline or treatment instruction. Our 2% comparison discussion likewise separates a product specification from evidence for a particular finished-product outcome. The clinical summary remains useful only when its group and endpoint stay attached.

A separate note describes consumer perception testing on 21 panelists over two weeks. In that block, 86% agreed about non-flaking and a smoother look and feel. Statements about reduced redness, improved imperfections and smaller-looking pores are presented without the same numerical figure. Assigning 86% to every line would misstate the record. Consumer block and footnote.

Nor should the 21 panelists be combined with the 31 clinical subjects to create a larger study population. The blocks report different groups and kinds of results. Keeping them separate allows readers to understand the favorable summaries while recognizing that perceived smoothness, breakout appearance and pore appearance are not automatically the same endpoint or measurement.

The fresh manufacturer page includes a Super Clear card showing $17. That card does not visibly attach a net quantity to the price in the returned material. The dated label separately contains a 30 mL pump-bottle package entry. Those observations should not be silently combined into a verified current price for the labeled package. Current price card and posted package entry.

FDA lists net contents as a separate piece of package information. A price needs a supported unit, and a package record does not establish which variant an untested order would fulfill. The plan-and-quantity guide examines that same reading problem without calculating an invented monthly expense. Package context.

Bubble describes a calm, hydrated and non-stripped skin feel. The label also warns that irritation or dryness can occur, particularly with other topical acne medication. That warning is part of the product record, even though the manufacturer highlights ingredients associated in its story with skin comfort. The review does not turn those descriptions into universal tolerability. Comfort claims and label warning.

AAD supplies broader context for dryness and irritation during salicylic-acid acne care. It does not test this serum or authorize a combination for an individual. A person’s concern therefore remains separate from whether a panel agreed with a favorable statement. AAD discussion.

The label identifies Bubble Beauty, an NDC number and an OTC monograph category. FDA explains that an NDC does not denote product approval or verification of the submitted information. The monograph framework also describes conditional marketing requirements, rather than an individual approval for every product carrying that record. Bubble identifier, NDC limits and monograph context.

The remaining questions concern the actual pump-label version and the complete report behind each distinct claim. Further entries are available in the Hero review and Starface review. They can help readers continue examining product records, without borrowing another brand’s evidence or choosing a winner from the number of claims on a page.